Biosyngen’s First-in-Class Drug Candidate BRG01 Accepted for IND Review
Biosyngen has announced that its investigational new drug (IND) filing for the first-in-class (FIC) drug...
Drug
Alphamab Oncology’s KN019 Achieves Primary Endpoint in Phase II RA Study
Suzhou-based biotech Alphamab Oncology (HKG: 9966) has announced that its China-based Phase II KN019-201 study,...
Staidson’s STSP-0601 Receives Clinical Trial Approval for Hemophilia Treatment
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...
Henlius Biotech Gets FDA Nod for HLX07 Clinical Study in CSCC
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the US...
Zelgen Files NDA for Jacktinib to Treat Myelofibrosis in China
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has filed a New...
Lepu Biotechnology’s MRG003 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received Breakthrough Therapy...
Lepu Biotechnology’s PD-1 Inhibitor HX008 Gains New Indication Approval
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received another indication...
Neurophth Biotechnology Doses First Patient in Phase III Trial for NR082
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that the first patient has been...
Bio-Thera Solutions Completes Phase I Study for COVID-19 Antibody BAT2022
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced the completion of all dosage groups (from 100...
Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has...
Arctic Vision Enrolls First Patient in Phase III Study for ARVN002
China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a...
Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and...
NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for...
Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China
China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...
Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...
Fosun Pharma Launches 20ml SPSB Liquid Product in US Market
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch...
Tris Pharma and Pediatrix Therapeutics’ ADHD Drug Gains Priority Review in China
The Center for Drug Evaluation (CDE) has indicated that the methylphenidate hydrochloride oral sustained-release dry...
Angel Pharmaceuticals Gains CDE Approval for Mupadolimab Phase I/Ib Study
China-based Angel Pharmaceuticals Ltd has announced that it has received approval from the Center for...
Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...
Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296
China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I...